• CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed
• Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution
• Report incorporates both CYB001 and CYB004 into valuation

As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy, people are paying attention. A recent Stifel report raised Cybin’s price target by C$12, up from C$4 to C$15, and maintained the company’s speculative buy rating (https://ibn.fm/HLcxX). “CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, including CYB004, with the announcement of two chosen indications, Social Anxiety Disorder (‘SAD’) and Generalized Anxiety Disorder (‘GAD’), some of the most common mental illnesses in the U.S,” the investment firm reported in its release. “We note CYB004 is a 2nd generation deuterated psychedelic molecule, offering strong potential for IP protection and a long period of outsized returns, in our view. “Currently, management expects CYB004 to enter Phase 1 clinical trials H1/22 with further research likely needed before determining whether to combine SAD and GAD into one clinical trial at the outset or to separate the two early on,” the report continued. “We now include CYB004 in our valuation for the first time, raising our target from $11 to $15, and reiterate our SPEC BUY rating given the large disconnect with the market, offering an attractive entry point.” As key points for its decision, Stifel pointed to the company selecting indications with large patient pools, a potentially understated market size, and the potential for multiple synergies across development and distribution. “CYBN has selected Social Anxiety Disorder (‘SAD’) and Generalized Anxiety Disorder (‘GAD’) as the initial target indications for its novel and proprietary psychedelic molecule CYB004,” the report stated. “SAD and GAD affect 3–7% of the U.S. population, putting both indications in line with the prevalence of Major Depressive Disorder, in our view, and representing a large potential patient pool.” Stifel pointed out that the global pandemic potentially increased these numbers, “with management indicating a 3-fold increase and the CDC suggesting symptoms of an anxiety or depressive disorder increased from 36.4% to 41.5% during the Aug. 2020–Feb. 2021 period (already in the height of the pandemic) with the percentage of those reporting an unmet mental health care need increased from 9.2% to 11.7%.” As for market size, the report noted that “whilemanagement indicated a potential global market size of ~US$4b for both indications combined, we believe the opportunity could be markedly higher. We note these estimates are based on the patient population seeking treatment with first-line therapy utilizing SSRI/SNRI antidepressants. However, we believe a majority of the patient population either does not seek treatment or does not receive appropriate treatment. . . . Hence, should CYB004 prove to be a more effective alternative with less side effects, its addressable market size could be larger than what we see currently.” Finally, Stifel also observed thatpatients dealing with anxiety commonly also have psychiatric co-morbidities with up to 80% of GAD patients also suffering from another mood disorder during their lifetime. “More specifically, we believe there could be a 50–60% probability that patients suffering from an anxiety disorder also have Major Depressive Disorder (‘MDD’). This could be a reason why antidepressants became a first-line treatment. Given CYBN’s primary drug candidate (‘CYB001’) focuses on MDD, we believe there are considerable drug development synergies where both clinical trials could share information, distribution/marketing channels, and have an overall higher chance of success,” the report stated. “We are incorporating CYB004 into our valuation for the first time through a 10-year, 2-stage DCF analysis with main assumptions including: successful launch FY28, pricing in-line with CYB001 & Spravato at ~$53k, addressing only the most severe anxiety cases, terminal growth of 2% and discount rate of 25%,” the report concluded. “As a result, our target increases from $11 to $15. SPEC BUY.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• The buyer loaded an initial 200.52 barrels of heavy crude and paid WTI pricing of $70.91 per barrel of crude oil produced at the company’s Asphalt Ridge facility
• Samples of the Asphalt Ridge crude are being sent to Quadrise Fuels International Plc in the UK for assessment to determine if it is suitable for the British company’s proprietary technology
• Petroteq and Greenfield are working with a local drilling fluids company for the identification of customers for the clean sand produced for use as a potential frac sand

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), an oil company focused on developing and implementing its proprietary oil extraction and reclamation technologies, has announced that the oil it produced at its Asphalt Ridge facility (the POSP) at the beginning of June 2021 has been sold and handed over to its buyer (https://ibn.fm/nJIYR). According to a company press release, the buyer paid West Texas Intermediate (‘WTI”) pricing of $70.91 per barrel, resulting in a net realized price of $57.91 per barrel after removing transportation costs of $13 per barrel. Due to trucking weight limitations, the buyer was only able to load 200.52 barrels of the10.2° API heavy crude produced at Asphalt Ridge. Commenting on the oil acquisition, George Stapleton, Petroteq COO, stated, “The fact that we were able to receive WTI pricing for the oil produced by the POSP demonstrates that the heavy, sweet (low sulfur) oil produced from Utah’s tar sands will likely command a premium price relative to other heavy oils. There also appears to be a market for our produced sand, which is a bonus.” The clean sands produced by the POSP can potentially be used as frac sand. Petroteq and Greenfield Energy, a 50/50 joint venture between TomCo Energy plc (AIM: TOM) and Valkor LLC, are currently working with a local drilling fluids company to identify customers for these clean sands. To date, the fluids company has taken an initial 40 tons and is expected to take an additional 700 tonnes over the coming weeks. Proceeds from this sand sale are expected to total approximately $15-$20 per ton. To further explore market opportunities for its produced oil, Petroteq is preparing a sample of its produced oil to ship to Quadrise Fuels International Plc in the UK. The purpose is to assess if the heavy, sweet oil produced by the POSP will be suitable for Quadrise’s MSAR(R) technology, a low viscosity oil-in-water emulsified synthetic heavy fuel oil obtained by mixing heavy residual oils with water and specific chemicals in a proprietary formulation. The sample is expected to leave the U.S. by the end of June 2021. Testing will be taking place following its arrival in the UK. Petroteq is engaged in developing and implementing its patented, proprietary technology that allows for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits, and shallow oil deposits while also expanding operations at the Asphalt Ridge facility. The source is nearer the surface and avoids the risk found in traditional drilling. Unlike traditional fracking, Petroteq’s technology focuses on heavy oil, which is currently in high demand. Most refineries are required to take a mixture of heavy and light oils, allowing them to provide a wide range of products, but Petroteq is uniquely positioned to help satisfy the heavy-oil gap. Petroteq’s green technology uses a small, modular footprint, which produces no greenhouse gases, does not require high temperatures, leaves only clean dry sand, and could be used to help unlock heavy oil deposits worldwide. Despite setbacks from the COVID-19 pandemic, the global oil demand is expected to rise to 104 million barrels per day (mb/d) by 2026, increasing 4% over 2019 totals (https://ibn.fm/xwP3w). To meet the oil growth demand, the supply will need to rise by 10 mb/d by the IEA’s projected date. For more information, visit the company’s website at www.Petroteq.com. NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus
• Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the virus
• DehydraTECH is a technology that helps drugs gain better bioavailability through effective introduction into patients’ bloodstreams
• The DehydraTECH platform has also shown great potential in enhancing hypertension medication and additional trials are ongoing

Pharmaceutical use and bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) recently reported it has achieved a major milestone in efficacy testing in combination with antiviral drugs that comprise a significant weapon in the war against COVID-19 infections, enhancing Lexaria’s potential for eventually partnering with a major pharmaceutical company as a drug delivery platform. Lexaria’s patented DehydraTECH technology strives to make swallowed pharmaceuticals more potent in their bloodstream bioavailability through creation of a select formulation that rivals the efficacy some substance users achieve only through smoking or inhaling products into the lungs — a potentially dangerous means of activating a drug’s potential. The company has reported trial successes working with blood pressure drugs and antivirals. Lexaria’s latest accomplishment involves testing DehydraTECH for the delivery of Remdesivir and Ebastine — antivirals that have gained renown in their use to reduce the harm wrought by COVID-19 SARS-CoV-2 during the past year’s global pandemic. In an in vitro IC50 study that measures the amount of a drug necessary to inhibit a biological process (https://ibn.fm/HgxOf) — specifically the amount of Remdesivir and Ebastine necessary to deliver a potent response against the COVID-19 SARS-CoV-2 virus — researchers found that DehydraTECH use as a delivery platform “did not negate the known efficacy of those compounds” (https://ibn.fm/VCm4E). While the testing is simply an early-stage analysis of whether DehydraTECH reduces the effectiveness of these drug treatments, Lexaria regards the successful results as an indicator that it is on the right track in seeking entry to the antiviral market, which is expected to achieve sales revenues of $44 billion within the next five years, according to analysts at by Global Market Insights Inc. (https://ibn.fm/5fpvp). Even before the advent of the COVID virus pandemic, health conditions such as influenza, HIV, respiratory syncytial virus (“RSV”), allergic rhinitis and other coronaviruses were expected to drive the market higher with a CAGR of 3.2 percent (https://ibn.fm/8TyOU) and Lexaria isn’t limiting its antiviral scope to studies involving COVID-19 drugs. “We needed to know if DehydraTECH(TM) interferes in any way with the effects these drugs have on the virus,” Lexaria Bioscience CEO Chris Bunka stated. “It doesn’t give us any direct score on ‘how well’ it works or does not, just a yes-no. The next step is to move on to in vivo efficacy testing in animals and then eventually humans.” However, testing has revealed that circulating drug levels of Remdesivir and Ebastine, enabled by DehydraTECH, were measured at two or three times their concentration levels in the non-DehydraTECH controls, providing Lexaria with the best results the company has “ever generated demonstrating our technology’s ability to more effectively deliver antiviral drugs when taken orally,” Bunka stated. When used with cannabidiol (“CBD”) in testing for hypertension strategies, the DehydraTECH-enhanced substance delivered a 5 percent drop in blood pressure after a single 90mg dose and a 300 percent greater concentration of CBD in under 30 minutes in 2018. A Phase I trial of the drug — HYPER-H21-1 — was completed ahead of schedule in June (https://ibn.fm/iLnR3) and that launch of Phase II trials was subsequently announced to determine time series blood pressure and heart rate effect. Lexaria has licensed its technology for use by a number of companies and has plans to also study DehydraTECH’s performance with non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors, human hormones, and vitamins. The company reported on its progress to investors at the Life Sciences Investor Forum conference series on June 24. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Infobird was featured in a recent SmallCapsDaily article that encouraged tech investors to grab IFBD’s stock as it looks to be a very compelling investment proposition
• This favorable outlook follows two new agreements announced within ten days and which represent the company’s diversification into the retail industry
• Infobird also expects its 2021 revenue will grow by 50% to between $22-$25 million
• The company is keen on accelerating the promotion of its marketing, customer service, and other related products in the retail industry

Infobird (NASDAQ: IFBD) was recently featured in an article by leading financial news website and publisher, SmallCapsDaily (https://ibn.fm/kJ6qB). Observing that the cloud computing domain commands the highest valuation, the piece notes that it has become extremely difficult to find reasonably priced stocks with cloud-oriented business models, particularly within the software-as-a-service (“SaaS”) market. Yet, IFBD trades at a “very cheap valuation, even below its IPO.” Even so, the article sheds light on a few elements that have not been factored into the current valuation, leading to the lower-than-expected valuation. These elements position IFBD as a very compelling investment proposition. Founded in 2001 and headquartered in Beijing, China, Infobird has grown over the years. It transitioned from its focus on call center services into a full-fledged tech solutions provider of customized AI-enabled, cloud-based customer engagement management solutions, having shifted from its initial standardized SaaS module model to a customized SaaS format recently. At the outset, Infobird, which also offers cloud-based sales force management software solutions, dealt primarily with companies in the financial services industry but has since expanded its focus into other sectors – its most recent diversification move is its entry into the retail industry. “Recently,” reads the article (https://ibn.fm/BSnPd) “Infobird issued two press releases announcing that it was awarded two new client assignments with large and well-known customers in the retail industry, a clear sign that the company is successfully executing its strategy of entering this new large and growing industry sector.” The Chinese retail sector has indeed witnessed growth over the last two decades. Valued at 3.9 trillion yuan ($557 billion at current exchange rates) in 2000, the sector grew to 36 trillion yuan ($5.6 trillion) in 2020 (https://ibn.fm/W0LA3). It is expected to expand further at an annual growth rate of 12.4% in 2021 and 7.1% in 2022 (https://ibn.fm/tnEZC). Through its strategic move, Infobird intends to help its clients achieve performance growth, in effect mirroring the sector’s upward trend. Further, as a company that is now committed to accelerating the promotion of its marketing, customer service, and other related products in the retail industry, these two assignments with Zu Li Jian and SaSa Cosmetics (China) Co., Ltd demonstrate its diversification strategy and cement its entry into this growing sector. Notably, the impact of this strategy extends beyond Infobird’s and its clients’ locus as it sends a clear message that IFBD “is aiming for the sky and is not expected to slow down its growth initiatives.” The article, which further notes that the announcement points to an undervaluation of IFBD’s stock, encourages tech investors to quickly seize the opportunity while the profitable SaaS stock is still cheap. “This [diversification] strategy, together with the expectation from the company that revenues for fiscal 2021, ending December 31, 2021, will be between $22 million and $25 million, an expected growth rate of more than 50% is why the company looks to be a very compelling investment proposition,” the article continues. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Company’s first line of NFTs features 17 unique pieces of artwork designed to highlight diversity within the music industry
• Each NFT opens royalty opportunities to holders for a catalog of over 50 different songs performed by top artists, including Rhianna, Justin Timberlake, Cher, Beyonce, Jay-Z, and Jane Zhang
• One ETH purchases an NFT and entry into the Music Mogul Club, offering exclusive membership benefits. The first 2100 NFT buyers gain access to the Music Mogul Club and additional membership benefits
• Staking into the royalty pools will begin in July 2021, with stakers earning royalties as early as Q3 2021

“Every Time It’s Played” is an appropriate name for the first line of non-fungible tokens (“NFTs”) released by entertainment fintech company and musi industry disruptor BAND Royalty, as the company’s music catalog offers over 50 songs that earn royalties for NFT holders every time they are played. The catalog includes songs performed by famous artists such as Rhianna, Justin Timberlake, Cher, Beyonce, Jay-Z, and Jane Zhang. The artists are not directly affiliated with BAND Royalty, which simply owns the royalties for the songs, allowing for royalty revenue whenever a song is played, no matter who the performer. The company’s first series of NFTs is currently for sale beginning at 1 ETH and also features 17 unique art pieces. The art represents the diversity in the music industry and is unique for this first line of NFTs. In addition, buyers who purchase an NFT for 1 ETH also gain access to BAND Royalty’s new Music Mogul Club. The first 2100 NFT buyers gain access to additional membership benefits. The Music Mogul Club offers NFT holders:

• Access to exclusive concerts
• Exclusive BAND merch
• First access to new NFTs
• Exclusive access to backstage events
• Festival passes
• Discounts on concerts
• Exclusive prize draws

Buyers can purchase NFTs through the company’s first-ever Music Only NFT Marketplace at https://bandroyalty.com/buynfts. After completing the purchase, users can register their NFT into the Music Mogul Club to take advantage of the exclusive member benefits. The access to the club opened in June 2021. As of July 2021, users can stake their NFT purchases in one of three royalty pools:

1. Publishing Royalties Pool
2. Mechanical and Public Performance Royalties Pool
3. Music Synchronization Royalties Pool

Each NFT must be staked for a minimum of 90 days, up to a maximum of five years. Stakers will be able to begin collecting royalties during Q3 2021. Stakers can earn up to 50% of royalties every time a song in the BAND Royalty catalog is played across all media channels. The current NFT series consists of eight different rarity levels for a total of only 3,000 NFTs. The largest is the Vinyl Album level (1,500 NFTs at 1 ETH each), stakeable in one royalty pool. Vinyl Gold Album (750 NFTs at 3 ETH each) and Gold Album (500 NFTs at 5 ETH) are stakeable in two royalty pools. Gold Platinum (225 NFTs at 7.5 ETH each) and Platinum Album (22 NFTs at 10 ETH each) are stakeable in all three royalty pools. The rarest categories – Platinum Diamond Album, Diamond Album, and Double Diamond Album, consisting of one NFT each at prices ranging from 15 to 25 ETH and, with access to all three royalty pools and tokens, are already sold out. The company intends to release up to 12,000 unique tokens across four series in the near future. The next series of NFTs is expected as early as July 2021. All revenue from these upcoming series will be used to expand BAND’s royalty library. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

Since being founded in 2017, the USA CBD Expo has established itself as the United States and South America’s leading CBD and Hemp conference series. Organizers of the show have routinely hosted hundreds of vendors from across the CBD value chain, the sector’s most significant brands as well as influential thought leaders and speakers. The most recent iteration of the USA CBD Expo was held at Atlanta’s immense Georgia World Congress Center – the third-largest convention center in the United States – between June 11-13^th, 2021, and proved to be a resounding success by all accounts, attracting thousands of attendees, over 300 vendors, and approximately 50 expert speakers drawn from across the CBD and hemp sectors. The state of Georgia, whose legal landscape currently allows medical marijuana consumers access to low-tetrahydrocannabinol (“THC”) CBD, boasts a slightly more permissive legal framework relative to its neighbors Alabama, Tennessee, and the Carolinas, which regard cannabis as fully illegal, and Florida, which has legalized medical marijuana for patients with select conditions. The progressive legal backdrop coupled with the growth of the industry within the state were all key factors influencing the conference’s location upon its return to an in-person format. This month’s Atlanta USA CBD Expo was split into two key sessions. The first day and a half were devoted to a B2B-only networking and investment-friendly get-together, followed by a subsequent one-and-a-half-day session focused on the event’s demos, buying opportunities, seminars, and keynote speakers. The conference once again distinguished itself for its multi-disciplinary offering, playing host to a diverse set of speakers, ranging from government insiders to advocates for veteran rights and benefits. Catering to a diverse audience comprised of both industry professionals as well as the general public, the seminars covered a variety of topics including an overview of the regulatory environment for CBD in Georgia, prospects for the CBD and hemp sectors going forward, as well as an in-depth analysis into the diverse business verticals within the industry. The USA CBD Expo series will next be held in Chicago between October 28-30, 2021. Seeking to bring together a rapidly expanding industry into a single, global trade show experience, the USA CBD Expo is committed to producing the best show possible to best advertise their exhibitors’ businesses, drive traffic to their respective booths, and get them closer to potential customers and new business ventures. For more information on future events, visit www.USACBDExpo.com.

• Nextech AR Solutions, a diversified leading provider of augmented reality (“AR”) experience technologies and services, is developing a platform for creating and publishing 3D images – at scale – from 2D originals, facilitating the digital transformation of online shopping and education
• Nextech recently announced the closing of its acquisition of AI 3D image mass producer Threedy.ai in an all-stock transaction valued at $9.5 million
• The combined efforts of the companies will remove a key bottleneck for e-commerce operators and manufacturers to create 3D models of their products at scale so that they can be easily marketed online via Web AR and on other smart devices
• Nextech’s immersive learning and video conference solution announced in June supports educators’ needs in transforming traditional learning and event formats into interactive digital learning experiences

Augmented reality (“AR”) ecosystem developer Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) has been making a name for itself developing 3D interactive experiential solutions that it expects to enhance e-commerce’s and higher education adoption and engagement. While the company’s AR platform may still be a little ways away from the capability of the intergalactic holographic video conferencing envisioned long ago by Hollywood’s “Star Wars” creator, Nextech is nonetheless advancing users’ ability to project human holograms and market products through 3D visualizations in cell phones, Web and other smart tech devices. Nextech’s potential to scale its 3D product took a significant leap in June when it closed on the acquisition of Silicon Valley-based artificial intelligence (“AI”) company Threedy.ai, Inc. The deal, finalized through the issuance of company shares valued at $9.5 million, will help Nextech toward its goal of creating “a disruptive, fully integrated, AR/AI enabled and scalable 3D modeling platform” suited to e-commerce customers, according to the company (https://ibn.fm/0Vzqk). “Retailers including Kohl’s, Pier1 and K-Mart Australia are already using Threedy’s technology to offer AR shopping experiences at scale and now together with Nextech we will create a unified, scalable 3D content creation engine for all our AR solutions,” Threedy CEO Nima Sarshar stated (https://ibn.fm/2j2td). “Threedy has created AI-powered tools that take 3D content creation for AR and other applications from a craft-production process to mass-production. It takes several hours for a typical 3D artist to create a 3D replica of a physical product. Content creation has long been the bottleneck for bringing AR to large retailers, many of whom have thousands of SKUs live at any given time. Using our virtual assembly line technology, thousands of models can be created per week, with minimal human intervention, in many categories.” Nextech’s technology stack also facilitates a more humanistic feel for the video-conferenced meetings that have become practically ubiquitous during the past year as a result of the COVID-19 pandemic. That includes educational solutions, as evidenced by Nextech’s announcement of its EdTechX solution the launch in June. The platform provides educational institutions with the technological means to turn their virtual experiences into evolved-beyond-the-white-board opportunities (https://ibn.fm/oDn8b). For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities
• POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space
• Predictive Oncology is strong standout in precision medicine

Predictive Oncology (NASDAQ: POAI) has closed on its registered direct offering (https://ibn.fm/9buhx).The offering, which totaled $21.34 million, will be a boon for the knowledge-driven company as it continues its focus on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. Operating in the AI space, the company is looking at almost vast potential as it focuses efforts on personalized medicine and drug discovery. The POAI portfolio is impressive, spanning four different subsidiaries — Helomics, TumorGenesis, Soluble Biotech and Skyline Medical — and including a list of assets that rivals the best operators in the space (https://ibn.fm/knRZc). Leveraging the unparalleled expertise and rich resources it has assembled, POAI has established one of the largest databases available of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (“CLIA”)-certified lab, and a novel approach to growing tumors in the lab that mimics the tumor in the patient’s own body. In addition, the company offers several innovative platforms, including a “smart” patient-derived tumor profiling platform; an in-house bioinformatics AI platform; and a comprehensive in silico platform, known as CORE and developed by top researchers from Carnegie Mellon University, that iteratively optimizes predictive models using a guided selection of experiments. Through its commitment to resources and innovative thinking, POAI has also gained a reputation for its expertise in specializing in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, a key piece of being able to move forward in personalize medicine, specifically in the cancer space. POAI has also become a recognized provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes, as well as endotoxin detection and removal. Finally, POAI has developed an FDA-approved fluid collection and disposal system. This strong portfolio makes POAI a strong standout in precision medicine, where precisely targeting drugs based on the genomic profile of the patient’s tumor, has become the aspiration for cancer therapy. “However, the reality is that while we can find many mutations in the patient’s tumor, most are not actionable with current drugs,” the company observes. “So, the race has begun to generate more data to understand which mutations are associated with what drug, in order to target therapy, a process that can take five to seven years of clinical evaluation to gather outcome data.” That’s where POAI enters the picture, “leveraging [its] unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment. “Predictive Oncology prospectively may have a competitive advantage,” the company concludes. “The company already has a substantial historical database of tumors and related data, plus the ability to obtain the associated outcome data. While others must wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine. Predictive Oncology presently has the clinical information, including tumor drug response data and an in-house bioinformatics AI platform.” POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development
• The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT
• It will focus on the psychedelics industry, showcasing the latest research and development within the sector
• Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline

In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development. The virtual event, scheduled on Wednesday, July 7, 2021, from 11:50 a.m. to 12:50 p.m. EDT, will focus on the psychedelics industry, mainly showcasing the latest research and development within the sector (https://ibn.fm/cihuB). The event is also intended to expand businesses currently looking for capital, mainly by directly delivering the industry’s most promising opportunities to funds and investors. The July 7 event marks the second global psychedelics industry investment event that solely focuses on research and development. As has been the case with the previous events, this one is meant to showcase the latest clinical evidence for this promising sector. It will feature a concise half-day program, with provisions for interactions with industry leaders, global psychedelics investors and rising entrepreneurs (https://ibn.fm/QN5e7). Tryp Therapeutics is a pharmaceutical enterprise committed to developing bioscience solutions for conditions with unmet needs (https://ibn.fm/VFGjr). Its current flagship program involves developing a synthetic psychedelic drug candidate specifically designed to treat particular pain and eating disorder indications. Its trademarked Psilocybin-for-Neuropsychiatric Disorder (“PFN”) program is the basis for the company’s development of treatments for several diseases that lack effective treatment options (https://ibn.fm/Ol6Tb). At this Psych Investor Summit, Tryp Therapeutics, through its Chairman and Chief Executive Officer, Mr. Greg McKee, will share the strides that it has made so far. More specifically, Mr. McKee will delve into more detail on Tryp’s drug development pipeline and what it is doing to push the envelope regarding the use of psychedelics to treat specific types of pain and diseases (https://ibn.fm/zZu5V). Mr. McKee will also contribute to a panel discussion on the future of research and development and the development activities for psychedelic drug compounds. Other speakers presenting at the conference include Rick Doblin, the Founder and Executive Director of MAPS; Christian Angermayer, the Founder of atai Life Sciences; and Dr. Ben Sessa, the Chief Medical Officer at Awkn Life Sciences. For more information, visit the company’s website at www.TrypTherapeutics.com. Should you wish to attend the summit, you can register at www.Psych.Global/agenda/. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Despite the worldwide economic difficulties imposed by the pandemic during the past year, new efforts at electric vehicle adoption are on the rise
• Ideanomics recently announced 100 percent acquisition of EV tractor manufacturer and distributor Solectrac Inc., which will grant it premium positioning in the agriculture industry’s growing interest in zero-emissions vehicles
• Ideanomics is also celebrating the launch of Technology Metals Market (“TM2”) trading using Nasdaq’s cloud-deployed matching technology for real-time pricing

Consumer interest in reducing the harmful effects of pollutants on the earth’s climate globally has led to a resurgence of electric-driven automotive technology in the world’s marketplace for private and commercial vehicles, nearly a century after the once-dominant electric vehicle industry became virtually extinct amid lower prices and mass production gains for gas-powered internal combustion engines (“ICEs”) (https://ibn.fm/1wJMo). While the United States has lagged somewhat in electric vehicle (“EV”) adoption compared to China and Northern Europe, and the COVID-19 pandemic has had a detrimental effect on new automotive sales this past year, the overall number of EV registrations in the United States still rose 36 percent during the first four months of 2021, according to an Automotive News report, and on a YOY basis for that period EV registrations rose 95 percent from 2020 (https://ibn.fm/im2Jd). New York-based company Ideanomics (NASDAQ: IDEX) is among a new wave of organizations injecting an estimated $16.3 billion overall into the EV start-up market this year — 28 per cent more than last year, according to market research company CB Insights (https://ibn.fm/QmWgH). Ideanomics’ announcement June 14 that it boosted its stake in California-based zero-emission electric tractors manufacturer and distributor Solectrac Inc. to 100 percent ownership (https://ibn.fm/ccJQb) not only highlighted applications of EV technology in the agricultural industry, but showcased Ideanomics’ drive to sustain next generation solutions for the world’s energy consumption and living standard equity difficulties. Solectrac has limited competition in the electric tractor market in North America, granting it a significant head start within the industry, the announcement states. Its premium electric tractor lineup is fully scalable and market-ready to generate revenue in the United States with proven demand. The announcement follows on the heels of Ideanomics’ acquisition of US Hybrid, a manufacturer of electric powertrain parts and fuel cell engines for heavy-duty municipal vehicles, commercial trucks, buses, and specialty cars (https://ibn.fm/ZoquR). “Ideanomics has emerged as a true powerhouse in the commercial EV sector with a synergistic ecosystem of technologies and solutions that covers the entire value chain of electrification,” US Hybrid CEO Gordon Abas Goodarzi stated in the news release announcing the deal. Ideanomics is also celebrating the launch of global technology metals marketplace trading platform Technology Metals Market (“TM2”), which is using Nasdaq’s cloud-deployed matching technology to provide investors with real-time pricing for trading a new asset class of high-value technology metals critical to global technology industries (https://ibn.fm/dH5BI). For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX